Oxford BioMedica Gene Therapy Clinical Trials Resume

November 20, 2013

Submit Comments
Irv Arons

I recently noted, both Oxford BioMedica and Genzyme had stopped recruiting for their respective gene therapy clinical trials this summer. Oxford announced the reason for its stoppage (a trace of contaminant found in a third-party supplied component), but no word from Genzyme (and no response to my attempts to find out).

Well, Oxford announced that it had resumed its clinical trial after receiving clearances from both the FDA and the French regulatory agency, ANSM.

For the story behind the story, please take a look at my write up.

And, Genzyme recently provided the answer for why it had stopped recruitment.

 

 

Print this post
 

Bookmark

 
Filed in Clinical Trials, Industry News, Macular Degeneration, NeuroOphthalmology, New Technologies, Products, Research, Retina


Comments

Jump down to form below to submit your own comments

Comments are closed.